4-benzyl 1-tert-butyl (2S,3R)-2-(3-hydroxypropyl)-3-isobutylbutanedioate | 191406-75-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-benzyl 1-tert-butyl (2S,3R)-2-(3-hydroxypropyl)-3-isobutylbutanedioate
• 英文别名: Benzyl 3S-(3-hydroxypropyl)-3-t-butoxycarbonyl-2(R)-isobutylpropanoate；4-O-benzyl 1-O-tert-butyl (2S,3R)-2-(3-hydroxypropyl)-3-(2-methylpropyl)butanedioate
• CAS: 191406-75-4
• 化学式: C₂₂H₃₄O₅
• 分子量: 378.509
• InChiKey: HLAWTGRLLOKOSZ-RBUKOAKNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  27
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-benzyl 1-tert-butyl (2S,3R)-2-(3-hydroxypropyl)-3-isobutylbutanedioate 在 palladium on activated charcoal N-甲基吗啉 、 lithium hydroxide 、 氢气 、 potassium carbonate 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 (8S,11R,12S)-11-Isobutyl-3-methyl-2,10-dioxo-1-oxa-3,9-diaza-cyclopentadecane-8,12-dicarboxylic acid 12-(benzyloxy-amide) 8-methylamide
  参考文献：
  名称：

  Design, Synthesis, and Structure−Activity Relationships of Macrocyclic Hydroxamic Acids That Inhibit Tumor Necrosis Factor α Release in Vitro and in Vivo

  摘要：

  To search for TNF-alpha (tumor necrosis factor alpha) converting enzyme (TACE) inhibitors, we designed a new class of macrocyclic hydroxamic acids by linking the PI and P2 ' residues of acyclic anti-succinate-based hydroxamic acids. A variety of residues including amide, carbamate, alkyl, sulfonamido, Boc-amino, and amino were found to be suitable P1-P2 ' linkers. With an N-methylamide at P3 ', the 13-16-membered macrocycles prepared exhibited low micromolar activities in the inhibition of TNF-alpha release from LPS-stimulated human whole blood. Further elaboration in the P3 ' -P4 ' area using the cyclophane and cyclic carbamate templates led to the identification of a number of potent analogues with IC50 values of less than or equal to 0.2 muM in whole blood assay (WBA). Although the P3 ' area can accommodate a broad array of structurally diversified functional groups including polar residues, hydrophobic residues, and amino and carboxylic acid moieties, in both the cyclophane series and the cyclic carbamate series, a glycine residue at P3 ' was identified as a critical structural component to achieve both good in vitro potency and good oral activity. With a glycine residue at P3 ', an N-methylamide at P4 ' provided the best cyclophane analogue, SL422 (WBA IC50 = 0.22 muM, LPS-mouse ED50 = 15 mg/kg, po), whereas a morpholinylamide at P4 ' afforded the most potent and most orally active cyclic carbamate analogue, SP057 (WBA IC50 = 0.067 muM, LPS-mouse ED50 = 2.3 mg/kg, po). Further profiling for SL422 and SP057 showed that these macrocyclic compounds are potent TACE inhibitors, with K-i values of 12 and 4.2 nM in the porcine TACE assay, and are broad-spectrum MMP inhibitors. Pharmacokinetic studies in beagle dogs revealed that SL422 and SP057 are orally bioavailable, with oral bioavailabilities of 11% and 23%, respectively.

  DOI：

  10.1021/jm010127e
• 作为产物：
  描述：

  (2R)-3-(tert-butoxycarbonyl)-2-isobutyl-5-hexenoic acid 在 9-borabicyclo[3.3.1]nonane dimer 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 16.33h， 生成 4-benzyl 1-tert-butyl (2S,3R)-2-(3-hydroxypropyl)-3-isobutylbutanedioate
  参考文献：
  名称：

  Design, Synthesis, and Structure−Activity Relationships of Macrocyclic Hydroxamic Acids That Inhibit Tumor Necrosis Factor α Release in Vitro and in Vivo

  摘要：

  To search for TNF-alpha (tumor necrosis factor alpha) converting enzyme (TACE) inhibitors, we designed a new class of macrocyclic hydroxamic acids by linking the PI and P2 ' residues of acyclic anti-succinate-based hydroxamic acids. A variety of residues including amide, carbamate, alkyl, sulfonamido, Boc-amino, and amino were found to be suitable P1-P2 ' linkers. With an N-methylamide at P3 ', the 13-16-membered macrocycles prepared exhibited low micromolar activities in the inhibition of TNF-alpha release from LPS-stimulated human whole blood. Further elaboration in the P3 ' -P4 ' area using the cyclophane and cyclic carbamate templates led to the identification of a number of potent analogues with IC50 values of less than or equal to 0.2 muM in whole blood assay (WBA). Although the P3 ' area can accommodate a broad array of structurally diversified functional groups including polar residues, hydrophobic residues, and amino and carboxylic acid moieties, in both the cyclophane series and the cyclic carbamate series, a glycine residue at P3 ' was identified as a critical structural component to achieve both good in vitro potency and good oral activity. With a glycine residue at P3 ', an N-methylamide at P4 ' provided the best cyclophane analogue, SL422 (WBA IC50 = 0.22 muM, LPS-mouse ED50 = 15 mg/kg, po), whereas a morpholinylamide at P4 ' afforded the most potent and most orally active cyclic carbamate analogue, SP057 (WBA IC50 = 0.067 muM, LPS-mouse ED50 = 2.3 mg/kg, po). Further profiling for SL422 and SP057 showed that these macrocyclic compounds are potent TACE inhibitors, with K-i values of 12 and 4.2 nM in the porcine TACE assay, and are broad-spectrum MMP inhibitors. Pharmacokinetic studies in beagle dogs revealed that SL422 and SP057 are orally bioavailable, with oral bioavailabilities of 11% and 23%, respectively.

  DOI：

  10.1021/jm010127e

文献信息

• [EN] NOVEL MATRIX METALLOPROTEINASE INHIBITORS AND IMAGING AGENTS, AND METHODS USING SAME<br/>[FR] NOUVEAUX INHIBITEURS DE MÉTALLOPROTÉINASES MATRICIELLES ET AGENTS D'IMAGERIE, ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：UNIV YALE

  公开号：WO2017177144A1

  公开（公告）日：2017-10-12

  The present invention provides certain compounds, Formula (I), or salts or solvates thereof, which can be used as matrix metalloproteinase-targeted inhibitors or imaging agents.

  本发明提供了某些化合物，化学式（I），或其盐或溶剂化合物，可用作基质金属蛋白酶靶向抑制剂或成像剂。
• [EN] METALLOPROTEINASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEASES
  申请人：BRITISH BIOTECH PHARMACEUTICALS LIMITED

  公开号：WO1999048881A1

  公开（公告）日：1999-09-30

  (EN) 2S-[(5-Dimethylaminonaphthalene-1-sulfonyl)-methyl-amino]-methyl}-5-methyl-3R-(morpholine-4-carbonyl)-hexanoic acid hydroxyamide and similar compounds are matrix metalloproteinase inhibitors.(FR) L'invention se rapporte à un hydroxyamide d'acide 2S-([(5-diméthylaminonaphtalène-1-sulfonyl)-méthyl-amino]-méthyl)-5-méthyl-3R-(morpholine-4-carbonyl)-hexanoïque ainsi qu'à des composés analogues qui sont des inhibiteurs de métalloprotéases matricielles.

  2S-3R-么orpholine-4-carbonyl-5-甲基- (5-二甲氨-1-丙基硫fonyl-7-氨基-苯并环甲基)苯并-outsime酸羟胺及其类似物是金属蛋白酶抑制剂。
• Hydroxamate-Based Selective Macrophage Elastase (MMP-12) Inhibitors and Radiotracers for Molecular Imaging
  作者：Kiran Gona、Jakub Toczek、Yunpeng Ye、Nowshin Sanzida、Arvene Golbazi、Parnaz Boodagh、Mani Salarian、Jae-Joon Jung、Saranya Rajendran、Gunjan Kukreja、Terence L. Wu、Laurent Devel、Mehran M. Sadeghi

  DOI：10.1021/acs.jmedchem.0c01514

  日期：2020.12.10

  Macrophage elastase [matrix metalloproteinase (MMP)-12] is the most upregulated MMP in abdominal aortic aneurysm (AAA) and, hence, MMP-12-targeted imaging may predict AAA progression and rupture risk. Here, we report the design, synthesis, and evaluation of three novel hydroxamate-based selective MMP-12 inhibitors (CGA, CGA-1, and AGA) and the methodology to obtain MMP-12 selectivity from hydroxamate-based panMMP inhibitors. Also, we report two ^99mTc-radiotracers, ^99mTc-AGA-1 and ^99mTc-AGA-2, derived from AGA. ^99mTc-AGA-2 displayed faster blood clearance in mice and better radiochemical stability compared to ^99mTc-AGA-1. Based on this, ^99mTc-AGA-2 was chosen as the lead tracer and tested in murine AAA. ^99mTc-AGA-2 uptake detected by autoradiography was significantly higher in AAA compared to normal aortic regions. Specific binding of the tracer to MMP-12 was demonstrated through ex vivo competition. Accordingly, this study introduces a novel family of selective MMP-12 inhibitors and tracers, paving the way for further development of these agents as therapeutic and imaging agents.
• Design and Synthesis of Cyclic Inhibitors of Matrix Metalloproteinases and TNF-α Production
  作者：Chu-Biao Xue、Xiaohua He、John Roderick、William F. DeGrado、Robert J. Cherney、Karl D. Hardman、David J. Nelson、Robert A. Copeland、Bruce D. Jaffee、Carl P. Decicco

  DOI：10.1021/jm970849z

  日期：1998.5.1
• Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-α production
  作者：Robert J. Cherney、Li Wang、Dayton T. Meyer、Chu-Biao Xue、Elizabeth C. Arner、Robert A. Copeland、Maryanne B. Covington、Karl D. Hardman、Zelda R. Wasserman、Bruce D. Jaffee、Carl P. Decicco

  DOI：10.1016/s0960-894x(99)00178-x

  日期：1999.5

  Several macrocyclic, hydroxamate derivatives were synthesized and evaluated as inhibitors of matrix metalloproteinases (MMPs) and tumour necrosis factor-alpha (TNF-alpha) production. These macrocycles are anti-succinate based inhibitors linked from P1 to P2'. A variety of functionality was installed at the P1-P2' linkage, which gave inhibitors that displayed excellent MMP inhibition and good TNF-alpha suppression. (C) 1999 DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.